Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0109-0012 phase 2b trial in anti-TNF inadequate responder rheumatoid arthritis
2012-000609-58Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fletikumab in rheumatoid arthritis (RA) (3 arms), sponsored by Novo Nordisk. Primary endpoint: ACR20 response. Started Jun 2012; status: completed.
02
Drugs
fletikumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2012-000609-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000609-58.